Antiepileptic drugs work by calming overactive electrical signals in the brain. They do this through a handful of core strategies: blocking the channels that let excited signals fire, boosting the brain’s natural braking system, or interfering with the release of chemical messengers that trigger seizures. Most drugs target one or two of these pathways, and the right choice depends on the type of seizure being treated.
Seizures as an Electrical Problem
A seizure happens when a large group of neurons fire together in an uncontrolled burst. Normally, the brain maintains a balance between excitatory signals (which make neurons fire) and inhibitory signals (which quiet them down). In epilepsy, that balance tips toward excitation, either because excitatory activity is too strong, inhibitory activity is too weak, or both. Every antiepileptic drug aims to restore that balance by targeting one side of the equation or the other.
Blocking Sodium Channels
The most common mechanism among antiepileptic drugs is sodium channel blockade. Sodium channels are tiny gates on the surface of neurons that open to let sodium ions rush in, triggering the electrical impulse that makes a neuron fire. During a seizure, neurons fire over and over at abnormally high rates. Drugs that target sodium channels don’t stop neurons from firing altogether. Instead, they lock onto the channel after it has just fired and hold it in an inactive state slightly longer than usual. This makes it harder for the neuron to fire again immediately, which selectively dampens the rapid, repetitive firing characteristic of seizures while leaving normal signaling mostly intact.
This mechanism is sometimes called “use-dependent blockade” because the drug binds more effectively to channels that are firing frequently. Neurons operating at normal rates are largely unaffected, which is why these drugs can reduce seizures without shutting down ordinary brain function. Older drugs like phenytoin and carbamazepine work this way. Newer drugs like lamotrigine also block sodium channels, with the added effect of reducing the release of glutamate, the brain’s primary excitatory chemical messenger.
Boosting the Brain’s Braking System
GABA is the brain’s main inhibitory neurotransmitter. When GABA binds to its receptor on a neuron, it opens a channel that lets negatively charged chloride ions flow into the cell. This makes the neuron’s interior more negative, pushing it further from the threshold needed to fire. The neuron essentially becomes harder to activate.
Benzodiazepines and barbiturates both enhance this process, but in slightly different ways. Benzodiazepines increase how often the chloride channel opens when GABA is present. Barbiturates increase how long the channel stays open each time. Either way, the result is stronger inhibition: neurons are quieter and less likely to join in the runaway firing of a seizure.
Other drugs boost GABA through different routes. Some block the enzyme that breaks GABA down, leaving more of it available in the gaps between neurons. The net effect is the same: more braking power in circuits that are firing too easily.
Blocking Calcium Channels
A specific type of calcium channel, called the T-type channel, plays a central role in absence seizures. These are the brief “staring spell” seizures most common in children. Deep in the brain, a circuit connecting the thalamus and cortex generates rhythmic electrical oscillations. T-type calcium channels in thalamic neurons drive these oscillations, producing the classic 3-per-second spike-and-wave pattern seen on an EEG during an absence seizure.
Ethosuximide works by blocking T-type calcium channels, disrupting the oscillatory loop that generates absence seizures. Valproate also reduces T-type calcium currents, which is one reason it can treat both absence seizures and other seizure types. Notably, sodium channel blockers are not effective for absence seizures and can sometimes make them worse.
Reducing Excitatory Signaling
Glutamate is the brain’s primary excitatory neurotransmitter. It binds to several types of receptors, the most important for epilepsy being AMPA and NMDA receptors. When glutamate activates these receptors, they allow positive ions to flood into the neuron, pushing it toward firing. Too much glutamate activity can tip the balance toward seizures. In animal studies, compounds that activate AMPA or NMDA receptors reliably cause seizures, while compounds that block them have anticonvulsant effects.
Perampanel is the most prominent drug that works this way. It blocks AMPA receptors, reducing the excitatory impact of glutamate at the synapse. This approach tackles seizures from the opposite direction compared to GABA-boosting drugs: rather than strengthening the brakes, it weakens the accelerator.
Targeting Neurotransmitter Release Directly
Levetiracetam stands apart from other antiepileptic drugs because of its unique target. Rather than acting on ion channels or neurotransmitter receptors, it binds to a protein called SV2A, which sits on the surface of synaptic vesicles (the tiny packets that store neurotransmitters inside nerve terminals). SV2A helps regulate how and when neurotransmitters are released into the synapse.
By binding to SV2A, levetiracetam appears to modulate the release of neurotransmitters in a way that reduces excessive signaling without broadly suppressing normal brain activity. The binding is reversible and highly specific. Studies in mice lacking the SV2A protein confirmed that it is the essential target: without it, the drug has nowhere to bind and loses its effect. This distinct mechanism is one reason levetiracetam tends to have a different side-effect profile compared to older drugs and why it interacts less with other medications.
Drugs That Combine Multiple Mechanisms
Some newer drugs work through more than one pathway simultaneously. Cenobamate, approved for focal-onset seizures in adults, is a clear example. It both blocks sodium channels and enhances GABA receptor activity. On the sodium channel side, it increases inactivation of both fast and slow channels, reducing repetitive neuronal firing. On the GABA side, it boosts the activity of several subtypes of GABA receptors, strengthening inhibition both at the synapse and in the surrounding area. This dual action on hippocampal neurons has been linked to its strong seizure-reducing effects in clinical trials.
Valproate is another multi-mechanism drug. It affects sodium channels, T-type calcium channels, and GABA metabolism, which helps explain its unusually broad effectiveness across different seizure types.
Why Seizure Type Determines Drug Choice
Different seizure types arise from different electrical disturbances, so the mechanism of a drug matters enormously when choosing treatment. Sodium channel blockers work well for focal seizures and generalized tonic-clonic seizures, where rapid repetitive firing is the core problem. But those same drugs, including carbamazepine, oxcarbazepine, phenytoin, and gabapentin, can actually worsen myoclonic seizures (the sudden, brief jerks that occur in some forms of generalized epilepsy). For absence seizures, T-type calcium channel blockers like ethosuximide are the most targeted option, while sodium channel blockers are ineffective or harmful.
Broad-spectrum drugs like valproate and levetiracetam are often chosen when a person has more than one seizure type or when the epilepsy syndrome isn’t fully classified, precisely because their mechanisms cover multiple pathways.
How Effective the First Drug Typically Is
For most people newly diagnosed with epilepsy, the first drug tried has a good chance of working. About 62% of patients become seizure-free on their first antiepileptic drug. If the first drug fails, the odds drop: roughly 42% achieve seizure freedom with a second drug, and only about 17% do so after trying two to five medications. After six or seven failed drugs, the chances of finding one that works on its own approach zero. This steep decline is why drug selection matters so much from the start and why, for people with drug-resistant epilepsy, other approaches like surgery or neurostimulation become important considerations.
Drug Interactions and Metabolism
Some antiepileptic drugs speed up the liver enzymes that metabolize other medications, which can reduce the effectiveness of those other drugs. Carbamazepine and phenytoin are the most notable enzyme inducers. Carbamazepine strongly ramps up certain liver enzymes, which can lower blood levels of hormonal contraceptives, blood thinners, immunosuppressants, and many other medications by 50% or more. Phenytoin has a similar profile. Phenobarbital also induces liver enzymes, though through a slightly different set.
Newer drugs like levetiracetam, lamotrigine, and gabapentin have fewer enzyme interactions, which makes them easier to combine with other treatments. If you take other daily medications, these interaction profiles often influence which antiepileptic drug your neurologist recommends, especially for people on chemotherapy, antiretrovirals, or birth control.